Kim Ji-Eun, Park Dong-Jin, Choi Sung-Eun, Kang Ji-Hyoun, Yim Yi-Rang, Lee Jeong-Won, Lee Kyung-Eun, Wen Lihui, Kim Seong-Kyu, Choe Jung-Yoon, Lee Shin-Seok
Division of Rheumatology, Department of Internal Medicine, Chonnam National University Medical School & Hospital, Gwangju, Republic of Korea.
Department of Internal Medicine, Catholic University of Daegu School of Medicine, Daegu, Republic of Korea.
Clin Exp Rheumatol. 2016 May-Jun;34(3):521-6. Epub 2016 Apr 13.
To determine the outcomes of Korean patients with fibromyalgia (FM) and to identify prognostic factors associated with improvement at 1-year follow-up.
Forty-eight patients with FM were enrolled and examined every 3 months for 1 year. At the time of enrollment, we interviewed all patients using a structured questionnaire that recorded socio-demographic data, current or past FM symptoms, and current use of relevant medications. Tender point counts and scores were assessed by thumb palpation. Patients were asked to complete the Korean versions of the Fibromyalgia Impact Questionnaire (FIQ), the Brief Fatigue Inventory, the SF-36, the Beck Depression Inventory, the State-Trait Anxiety Inventory (STAI), the Self-Efficacy Scale, and the Social Support Scale. Tender points, FIQ scores, and the use of relevant medications were recorded during one year of follow-up.
Of the 48 patients, 32 (66.7%) had improved FIQ scores 1 year after enrollment. Improved patients had higher baseline FIQ scores (68.4±13.9 vs. 48.4±20.8, p=0.001) and STAI-II scores (55.8±10.9 vs. 11.5±11.5, p=0.022). Patients treated with pregabalin were more likely to improve after 1 year, based on the FIQ scores (71.9% vs. 37.5%, p=0.031). On multivariate logistic regression analysis, a higher STAI-II score at the time of enrollment and pregabalin treatment during one year of follow-up were the predictors of improvement.
Two-thirds of our Korean FM patients experienced some clinical improvement by 1-year follow-up. A high baseline STAI-II score and treatment with pregabalin were the important predictor of improved FM.
确定韩国纤维肌痛（FM）患者的治疗结果，并识别与1年随访时病情改善相关的预后因素。
招募了48例FM患者，在1年时间里每3个月进行一次检查。在入组时，我们使用结构化问卷对所有患者进行访谈，记录社会人口统计学数据、当前或过去的FM症状以及当前相关药物的使用情况。通过拇指触诊评估压痛点计数和评分。要求患者完成纤维肌痛影响问卷（FIQ）、简明疲劳量表、SF-36、贝克抑郁量表、状态-特质焦虑量表（STAI）、自我效能量表和社会支持量表的韩文版。在1年的随访期间记录压痛点、FIQ评分和相关药物的使用情况。
48例患者中，32例（66.7%）在入组1年后FIQ评分有所改善。病情改善的患者基线FIQ评分较高（68.4±13.9对48.4±20.8，p=0.001）以及STAI-II评分较高（55.8±10.9对11.5±11.5，p=0.022）。根据FIQ评分，接受普瑞巴林治疗的患者在1年后更有可能病情改善（71.9%对37.5%，p=0.031）。多因素逻辑回归分析显示，入组时较高的STAI-II评分和随访1年期间接受普瑞巴林治疗是病情改善的预测因素。
我们的韩国FM患者中有三分之二在1年随访时出现了一定程度的临床改善。较高的基线STAI-II评分和普瑞巴林治疗是FM病情改善的重要预测因素。
